Table 1.

Prevalence of allergic disease and aeroallergen sensitization outcomes in the IOW cohort and FLG-genotyped subpopulation

	Total IOW cohort n/N (%)	FLG-genotyped subpopulation n/N (%)	p value
Gender
Male	786/1536 (51.2)	569/1150 (49.5)	0.38
Female	750/1536 (48.8)	581/1150 (50.5)	0.38
Eczema
1 year	182/1364 (13.3)	145/1065 (13.6)	0.85
2 years	259/1227 (21.1)	209/978 (21.2)	0.88
4 years	147/1214 (12.1)	121/1008 (12.0)	0.94
10 years	186/1358 (13.7)	164/1117 (14.6)	0.48
18 years	161/1307 (12.3)	132/1086 (14.2)	0.90
Asthma
4 years	182/1214 (15.0)	151/1006 (15.0)	1.0
10 years	201/1368 (14.7)	136/1016 (13.4)	0.37
18 years	231/1305 (17.7)#	162/973 (16.6)	0.49
Rhinitis
4 years	66/1214 (5.4)	51/1007 (5.1)	0.75
10 years	205/1362 (15.1)	184/1121 (16.4)	0.38
18 years	468/1309 (35.8)^	405/1087 (37.3)	0.45
Positive Aeroallergen sensitization
1 or 2 years	79/563 (14.0)	71/473 (15.0)	0.65
4 years	170/980 (17.3)	119/725 (16.4)	0.62
10 years	276/1035 (26.7)	197/765 (25.8)	0.67
18 years	343/851 (40.3)¥	248/628 (39.5)	0.76

n: number of patients with specified characteristic or disease; N: total number of patients with available data for analysis at a specified time-point; %: prevalence

^#There was a significant increase in prevalence of asthma from 10 to 18 years (p = 0.005).

^{^}Rhinitis increased in prevalence from 4 to 18 years (p < 0.001).

^¥Aeroallergen sensitization increased in prevalence from 4 to 18 years (p < 0.001).